Subdermal progestin implant (Nestorone ® ) in the treatment of endometriosis: clinical response to various doses

References

• Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand 1993; 72: 324–36.
   Google Scholar
• Olive DL, Schwartz LB. Medical progress – Endometriosis. New Engl J Med 1993; 328: 1759–69.
   Google Scholar
• Farquhar C, Sutton C. The evidence for the management of endometriosis. Curr Opin Obstet Gynecol 1998; 10: 321–32.
   Google Scholar
• Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68: 393–401.
   Google Scholar
• Telimaa S, Apter D, Reinilä M, Rönnberg L, Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynecol Reprod Biol 1990; 36: 97–105.
   Google Scholar
• Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993; 59: 511–5.
   Google Scholar
• Coutinho EM, Da Silva AR, Carreira CMV, Silvin J. Long-term contraception with a single implant of the progestin ST-1435. Fertil Steril 1981; 36: 737–40.
   Google Scholar
• Laurikka-Routti M, Haukkamaa M. A contraceptive subdermal implant releasing the progestin ST 1435. Ovarian function, bleeding patterns and side-effects. Fertil Steril 1992; 58: 1142–7.
   Google Scholar
• Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring. releasing ethinyl estradiol and the progestin ST-1435: Bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 1990; 42: 111–20.
   Google Scholar
• Laurikka-Routti M, Haukkamaa M, Lähteenmäki P. Suppression of ovarian function with the transdermally given synthetic progestin ST-1992. Fertil Steril 1995; 58: 680–4.
   Google Scholar
• Diaz S, Schiappacasse V, Pavez M, Zepeda A, Moo-Young AJ, Brandeis A et al. Clinical trial with Nestorone™ subdermal contraceptive implants. Contraception 1995; 51: 33–8.
   Google Scholar
• Lähteenmäki PLA, Lähteenmäki P. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1985. Fertil Steril 1991; 44: 20–4.
   Google Scholar
• Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection. life table analysis of reoperation and persistent or recurrent disease. Fertil Steril 1997; 65: 628–34.
   Google Scholar
• Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1999; 68: 860–4.
   Google Scholar
• Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 1985; 106: 672–7.
   Google Scholar
• American Fertility Society. Revised American Fertility Society Classification of Endometriosis. Fertil Steril 1972; 43: 351–2.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1989; 18: 499–502.
   Google Scholar
• Shoupe D, Mishell DR Jr. Norplant: subdermal implant system for long-term contraception. Am J Obstet Gynecol 1986; 160: 1286–92.
   Google Scholar
• Fåhraeus L, Sydsjö A, Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 1987; 45: 503–6.
   Google Scholar
• Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and highdose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1: 13–23.
   Google Scholar
• Brosens IA. Endometriosis-A disease because it is characterized by bleeding. Am J Obstet Gynecol 1997; 176: 263–7.
   Google Scholar
• Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998; 69: 1056–62.
   Google Scholar
• Schmidt CL. Endometriosis: a reappraisal of pathogenesis and treatment. Fertil Steril 1985; 44: 157–73.
   Google Scholar
• Telimaa S, Rönnberg L, Kauppila A. Placebocontrolled comparison of danazol and high-dose medroxyprogesterone acetate in the postoperative treatment of endometriosis. Gynecol Endocrinol 1987; 1: 363–71.
   Google Scholar
• Dmowski WP, Cohen MR. Antigonadotropin (Danazol) in the treatment of endometriosis: Evaluation of posttreatment fertility and three-year follow-up data. Am J Obstet Gynecol 1978; 130: 40–8.
   Google Scholar
• Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485–8.
   Google Scholar